Posted inClinical Updates news Oncology
Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma: Evidence, Outcomes, and Clinical Perspectives
This review synthesizes recent evidence on immune checkpoint inhibitor (ICI)-based downstaging therapy for hepatocellular carcinoma (HCC) beyond Milan criteria prior to liver transplantation, highlighting improved oncologic outcomes alongside acute rejection risks.